HTL to Invest in Production Facility for Injectable Grade Sodium Hyaluronate
The new Javené, France-based facility is expected to increase the company’s production capacity of injectable grade sodium hyaluronate obtained by fermentation by 2.5 times.
HTL, a hyaluronic acid and biopolymer solutions supplier based in France, announced it will invest in a production facility for injectable grade sodium hyaluronate production. Financial details of the investment were not disclosed.
The new Javené, France-based facility is expected to increase the company’s production capacity of injectable grade sodium hyaluronate obtained by fermentation by 2.5 times by 2021, the company said in an Oct. 30, 2019 press release. It will also boost the global marketing of the company’s medical applications and biopolymer-based innovation.
“This new, unprecedented capacity investment demonstrates the long-term commitment of HTL and its shareholders to anticipate and fulfill the growing needs of its customers worldwide,” said Yvon Bastard, CEO of HTL, in the press release.
HTL will be exhibiting at CPhI Worldwide from Nov. 5–7, 2019 at stand 4.2G13.
Source: HTL
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
